News archive for Structural biology and drug discovery

As part of a consortium lead by the EU-Openscreen head office with the overall goal to improve the services offered by EU-Openscreen, the Brenk group has got funding to work on Ribotacs. Ribotacs are small molecules that selectively bind RNAs and a RNAse and thus lead targeted RNA degradation. We look forward to a succesfull collaboration.